Tirzepatide

Generic Name: Tirzepatide

Brand Names: Mounjaro

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2023788-19-2

Unique Ingredient Identifier: OYN3CCI6QE

Background: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...

Indication: Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Phase 2

Recruiting

Conditions: T2D
Obesity
Chronic Kidney Disease
Type 2 Diabetes
Overweight

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2022-09-13

Last Posted Date: 2024-12-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 140

Registration Number: NCT05536804

Locations: 🇺🇸
American Health Network of Indiana, LLC - Avon, Avon, Indiana, United States
🇨🇦
Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T, Sherbrooke, Quebec, Canada
🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States

and more 25 locations

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Phase 4

Active, not recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Antihyperglycemic medication
Drug: Tirzepatide

First Posted Date: 2022-06-27

Last Posted Date: 2024-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 780

Registration Number: NCT05433584

Locations: 🇺🇸
New England Research Associates, LLC, Bridgeport, Connecticut, United States
🇺🇸
Velocity Clinical Research, San Diego, La Mesa, California, United States
🇺🇸
Research Foundation of SUNY - University of Buffalo, Buffalo, New York, United States

and more 87 locations

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Phase 3

Completed

Conditions: Sleep Apnea
Obesity

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2022-06-09

Last Posted Date: 2024-05-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 469

Registration Number: NCT05412004

Locations: 🇺🇸
NeuroScience Research Center, Canton, Ohio, United States
🇧🇷
BR Trials - Ensaios Clinicos e Consultoria, São Paulo, Brazil
🇩🇪
InnoDiab Forschung Gmbh, Essen, Nordrhein-Westfalen, Germany

and more 54 locations

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

Phase 3

Completed

Conditions: Overweight
Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2021-08-27

Last Posted Date: 2024-01-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 210

Registration Number: NCT05024032

Locations: 🇨🇳
The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳
Zhujiang Hospital, Guangzhou, Guangdong, China
🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China

and more 26 locations

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Phase 3

Completed

Conditions: Obesity
Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2021-04-19

Last Posted Date: 2024-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 731

Registration Number: NCT04847557

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Northwest Houston Heart Center, Tomball, Texas, United States
🇺🇸
Excel Medical Clinical Trials, Boca Raton, Florida, United States

and more 140 locations

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Phase 3

Completed

Conditions: Obesity

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2021-04-14

Last Posted Date: 2024-07-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 267

Registration Number: NCT04844918

Locations: 🇯🇵
Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan
🇯🇵
Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan
🇯🇵
Motomachi Takatsuka Naika Clinic, Yokohama-city, Kanagawa, Japan

and more 15 locations

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Phase 3

Completed

Conditions: Overweight
Obesity

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2020-12-09

Last Posted Date: 2024-05-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 783

Registration Number: NCT04660643

Locations: 🇺🇸
North Texas Endocrine Center, Dallas, Texas, United States
🇺🇸
Tribe Clinical Research, LLC, Greenville, South Carolina, United States
🇺🇸
Glacier View Research Institute - Endocrinology, Kalispell, Montana, United States

and more 67 locations

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2020-12-07

Last Posted Date: 2024-05-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 579

Registration Number: NCT04657016

Locations: 🇺🇸
National Research Institute (NRI) - Santa Ana, Santa Ana, California, United States
🇺🇸
Texas Diabetes & Endocrinology, P.A., Round Rock, Texas, United States
🇺🇸
Metabolic Research Institute, Inc., West Palm Beach, Florida, United States

and more 59 locations

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Phase 3

Completed

Conditions: Overweight
Type 2 Diabetes
Obesity

Interventions: Other: Placebo
Drug: Tirzepatide

First Posted Date: 2020-12-07

Last Posted Date: 2024-04-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 938

Registration Number: NCT04657003

Locations: 🇺🇸
Emory University School of Medicine- Grady Campus, Atlanta, Georgia, United States
🇺🇸
PharmQuest, Greensboro, North Carolina, United States
🇺🇸
East Coast Institute for Research, LLC, Macon, Georgia, United States

and more 72 locations

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Insulin Lispro (U100)
Drug: Tirzepatide

First Posted Date: 2020-09-03

Last Posted Date: 2023-11-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1428

Registration Number: NCT04537923

Locations: 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸
Metabolic Research Institute, Inc., West Palm Beach, Florida, United States
🇺🇸
J H. Stroger Hosp of Cook Co, Chicago, Illinois, United States

and more 130 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy